Literature DB >> 8151462

Intramuscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia.

G R Fleisher1, N Rosenberg, R Vinci, J Steinberg, K Powell, C Christy, D A Boenning, G Overturf, D Jaffe, R Platt.   

Abstract

Because studies of the treatment of children with occult bacteremia have yielded conflicting results, we compared ceftriaxone with amoxicillin for therapy. Inclusion criteria were age 3 to 36 months, temperature > or = 39 degrees C, an acute febrile illness with no focal findings or with otitis media (6/10 centers), and culture of blood. Subjects were randomly assigned to receive either ceftriaxone, 50 mg/kg intramuscularly, or amoxicillin, 20 mg/kg/dose orally for six doses. Of 6733 patients enrolled, 195 had bacteremia and 192 were evaluable: 164 Streptococcus pneumoniae, 9 Haemophilus influenzae type b, 7 Salmonella, 2 Neisseria meningitidis, and 10 other. After treatment, three patients receiving amoxicillin had the same organism isolated from their blood (two H. influenzae type b, one Salmonella) and two from the spinal fluid (two H. influenzae type b), compared with none given ceftriaxone. Probable or definite infections occurred in three children treated with ceftriaxone and six given amoxicillin (adjusted odds ratio 0.43, 95% confidence interval 0.08 to 1.82, p = 0.31). The five children with definite bacterial infections (three meningitis, one pneumonia, one sepsis) received amoxicillin (adjusted odds ratio 0.00, 95% confidence interval 0.00 to 0.52, p = 0.02). Fever persisted less often with ceftriaxone (adjusted odds ratio 0.52, 95% confidence interval 0.28 to 0.94, p = 0.04). Although the difference in total infections was not significant, ceftriaxone eradicated bacteremia, prevented significantly more definite focal bacterial complications, and was associated with less persistent fever.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151462     DOI: 10.1016/s0022-3476(05)83126-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Shared decision making in pediatrics.

Authors:  H Bauchner
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

2.  Clinical epidemiological principles in bedside teaching.

Authors:  J G Ruiz; J M Lozano
Journal:  Indian J Pediatr       Date:  2000-01       Impact factor: 1.967

Review 3.  Unexplained fever in young children: how to manage severe bacterial infection.

Authors:  Itzhak Brook
Journal:  BMJ       Date:  2003-11-08

Review 4.  Management of the non-toxic-appearing acutely febrile child: a 21st century approach.

Authors:  Ravi Jhaveri; Carrie L Byington; Jerome O Klein; Eugene D Shapiro
Journal:  J Pediatr       Date:  2011-05-17       Impact factor: 4.406

Review 5.  Rational prescribing of antibacterials in hospitalised children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

6.  Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring.

Authors:  D Benador; T J Neuhaus; J P Papazyan; U V Willi; I Engel-Bicik; D Nadal; D Slosman; B Mermillod; E Girardin
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

Review 7.  Aetiology and management of children with acute fever of unknown origin.

Authors:  G O Akpede; G I Akenzua
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 8.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Approach to the febrile child: A challenge bridging the gap between the literature and clinical practice.

Authors:  Jean-Bernard Girodias; Benoit Bailey
Journal:  Paediatr Child Health       Date:  2003-02       Impact factor: 2.253

10.  Clinical management of fever in children younger than three years of age.

Authors:  Martin V Pusic
Journal:  Paediatr Child Health       Date:  2007-07       Impact factor: 2.253

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.